Registered outcomes15

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 15 of 15

List	Outcome	Time frame	Description
Primary	Evaluate effectiveness of emetine in dengue patients assessed by 28-day mortality or progression	28 days	28-day mortality or progression to severe dengue, defined as severe plasma leakage, severe bleeding, or severe organ involvement (death and severe dengue will be assessed as a composite outcome)
Primary	Safety of emetine assessed by number of adverse events	Up to 28 days	Record serious adverse events and toxicities by organ-system
Primary	Safety of emetine assessed by rate of drug discontinuation	Up to 28 days	Evaluate the safety of emetine assessed by rate of drug discontinuation
Secondary	Recovery (≥ 3 days without symptoms)	Up to 14 days	Sustained resolution of all dengue symptoms for ≥ 3 consecutive days (where the first of those days is considered the date of recovery)
Secondary	Time to Virologic Clearance of Dengue Virus by Qualitative RT-PCR	Pre-dose (day 0), day 3, and day 5	Time to test negativity that is longitudinally measured by Qualitative real-time polymerase chain reaction (RT-PCR).
Secondary	Quantitative Viral Load Assessment by RT-PCR Cycle Threshold (Ct) Values	Days 0,3, 5	Measures of the average RT-PCR cycle threshold (Ct) values for dengue virus RNA at specified time points post-randomization.
Secondary	Changes in inflammatory marker measured by hematocrit	Days 0 to 5	Measure hematocrit in percentage (%) for patients
Secondary	Changes in inflammatory marker measured by white blood count	Day 0-5	Measure white blood count (WBC) for patients measured per microliter (mcL)
Secondary	Changes in inflammatory marker measured by reticulocyte count	Day 0-5	Measure reticulocyte count as percentage (%) for patients
Secondary	Changes in inflammatory marker measured by platelet count	Day 0-5	Measure platelet count for patients measured per microliter (mcL)
Secondary	Changes in inflammatory marker measured by alanine aminotransferase	Day 0-5	Measure alanine aminotransferase (ALT) for patients in units per liter (U/L)
Secondary	Changes in inflammatory marker measured by serum bilirubin	Day 0-5	Measure serum bilirubin for patients in milligrams per deciliter (mg/dL)
Secondary	Changes in inflammatory marker measured by serum albumin	Day 0-5	Measure serum albumin for patients in grams per deciliter (g/dL)
Secondary	Changes in inflammatory marker measured by C-reactive protein	Day 0-5	Measure C-reactive protein (CRP) for patients in milligrams per liter (mg/L)
Secondary	Post infection fatigue measured by Fatigue Questionnaire	On Day 28	Fatigue will be measured using the validated 11-item Fatigue Questionnaire (FQ), which assesses both physical (7 items) and mental (4 items) fatigue. Each item is rated on a 4-point Likert scale (0 = none, 3 = severe), with total scores ranging from 0 to 33, where higher scores indicate greater fatigue severity.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07016321/registered

API reference For AI assistants